Daily Endocrinology Research Analysis
Three impactful endocrinology-adjacent studies stood out today: a Nature Medicine multi-trait GWAS reframes obesity as genetically heterogeneous with adiposity uncoupled from cardiometabolic risk; a multinational cohort shows extreme Lp(a) confers cardiovascular risk equivalence in heterozygous familial hypercholesterolemia; and a nationwide matched cohort finds preoperative GLP-1 RA use is associated with fewer perioperative respiratory complications.
Summary
Three impactful endocrinology-adjacent studies stood out today: a Nature Medicine multi-trait GWAS reframes obesity as genetically heterogeneous with adiposity uncoupled from cardiometabolic risk; a multinational cohort shows extreme Lp(a) confers cardiovascular risk equivalence in heterozygous familial hypercholesterolemia; and a nationwide matched cohort finds preoperative GLP-1 RA use is associated with fewer perioperative respiratory complications.
Research Themes
- Precision genetics of obesity and cardiometabolic uncoupling
- Lipoprotein(a) thresholds and aggressive risk management in HeFH
- Perioperative safety of GLP-1 receptor agonists in type 2 diabetes
Selected Articles
1. Genetic subtyping of obesity reveals biological insights into the uncoupling of adiposity from its cardiometabolic comorbidities.
Using individual-level data from 452,768 UK Biobank participants, the authors performed a multi-trait GWAS and defined continuous phenotypes that quantify the uncoupling of adiposity from cardiometabolic status. They identified 266 variants across 205 loci where adiposity-increasing alleles are associated with lower cardiometabolic risk and initiated development of a genetic risk score capturing this uncoupling.
Impact: This reframes obesity as genetically heterogeneous and uncoupled from cardiometabolic disease in many individuals, challenging BMI-centric risk assumptions and enabling precision risk stratification.
Clinical Implications: While immediate practice change is limited, genetic subtyping could refine cardiometabolic risk prediction at a given BMI, inform tailored prevention, and guide therapeutic prioritization once validated and integrated into clinical tools.
Key Findings
- Multi-trait GWAS in 452,768 UK Biobank participants defined continuous phenotypes capturing adiposity–cardiometabolic uncoupling.
- Identified 266 variants across 205 genomic loci where adiposity-increasing alleles were associated with lower cardiometabolic risk.
- Initiated development of a genetic risk score (GRS) to quantify the uncoupling phenotype.
Methodological Strengths
- Very large individual-level dataset enabling robust multi-trait modeling
- Novel continuous phenotype approach to quantify adiposity–risk uncoupling
Limitations
- Predominantly UK Biobank population may limit generalizability across ancestries
- Observational genetic associations cannot establish causality or immediate clinical utility
Future Directions: Validate findings across diverse ancestries, dissect causal mechanisms, and test whether GRS-based subtyping improves risk prediction and treatment targeting in prospective clinical studies.
Obesity is a heterogeneous condition not adequately captured by a single adiposity trait. We conducted a multi-trait genome-wide association analysis using individual-level data from 452,768 UK Biobank participants to study obesity in relation to cardiometabolic health. We defined continuous 'uncoupling phenotypes', ranging from high adiposity with healthy cardiometabolic profiles to low adiposity with unhealthy ones. We identified 266 variants across 205 genomic loci where adiposity-increasing alleles were simultaneously associated with lower cardiometabolic risk. A genetic risk score (GRS
2. Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia.
In 2,979 primary-prevention HeFH patients from France, the UK, and Canada, the 90th percentile Lp(a) (≥100 mg/dL; ≥250 nmol/L) conferred a 10-year ASCVD risk of 28.7%, approaching the 34.9% risk seen in non-FH secondary prevention. This supports using extreme Lp(a) as a cardiovascular risk equivalent to guide aggressive therapy.
Impact: Identifying an actionable Lp(a) threshold in HeFH provides a clear, data-driven basis for intensified treatment and future uptake of Lp(a)-targeted therapies.
Clinical Implications: Measure Lp(a) in all HeFH patients; those ≥100 mg/dL (≥250 nmol/L) should receive aggressive ASCVD prevention (maximized LDL-C lowering, consideration of apheresis where appropriate) and are prime candidates for emerging Lp(a)-lowering agents.
Key Findings
- In primary-prevention HeFH, the 90th percentile Lp(a) was ≥100 mg/dL (≥250 nmol/L).
- Lp(a) ≥100 mg/dL was associated with a 10-year ASCVD risk of 28.7% vs 11.0% for <100 mg/dL.
- This risk approaches that of non-FH individuals in secondary prevention (34.9%), supporting a risk-equivalence concept.
Methodological Strengths
- Multinational analysis of three prospective cohorts with standardized event assessment
- Inclusion of genetically or clinically defined HeFH with appropriate time-to-event methods
Limitations
- Observational design with potential residual confounding and treatment heterogeneity
- Between-cohort differences and Lp(a) assay variability may affect threshold generalizability
Future Directions: Assess how incorporating Lp(a) ≥100 mg/dL into risk algorithms changes outcomes, and evaluate benefits of Lp(a)-lowering therapies in this extreme-risk HeFH subgroup.
BACKGROUND: Extreme elevations in lipoprotein(a) [Lp(a)] and familial hypercholesterolemia (FH) are both monogenic diseases associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). The identification of high Lp(a) risk thresholds would help to improve risk assessment in subjects with heterozygous FH (HeFH). OBJECTIVE: To find the Lp(a) value at which the observed 10-year ASCVD risk corresponds to a cardiovascular risk equivalent in a cohort of HeFH patients in primary cardiovascular prevention. METHODS: This multinational observational study used data from 3 prospective cohorts from France, UK, and Canada. A total of 2979 adult patients with HeFH in primary prevention diagnosed using genetic or clinical criteria (Dutch Lipid Clinic Network score ≥6) and 10,521 non-FH control participants in secondary cardiovascular prevention were included in the study. The 10-year risk of incident ASCVD was assessed using Kaplan-Meier estimates, whereas the relative risk was estimated using Cox proportional hazards regression models. RESULTS: The 90th percentile of Lp(a) in the group of FH subjects in primary prevention corresponds to ≥100 mg/dL (≥250 nmol/L). The observed 10-year risk of ASCVD associated with an Lp(a) ≥100 mg/dL (≥250 nmol/L) vs <100 mg/dL (<250 nmol/L) was 28.7% and 11.0%, respectively, compared to 34.9% in non-FH individuals in secondary cardiovascular prevention. CONCLUSION: This study showed that 10% of HeFH in primary cardiovascular prevention have an extreme cardiovascular risk associated with the presence of a double monogenic dyslipidemia. These individuals should be treated more aggressively to prevent ASCVD and may greatly benefit from novel therapeutics targeting Lp(a).
3. Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus: a nationwide propensity-score matched study.
In 296,389 matched pairs of adults with type 2 diabetes, preoperative GLP-1 RA use was associated with fewer 30-day postoperative respiratory complications (0.09% vs 0.34%; RR 0.26) and less aspiration (0.01% vs 0.03%; RR 0.31). Associations were consistent for long- and short-acting agents.
Impact: Addresses a pressing perioperative safety concern for widely used GLP-1 RAs with robust real-world evidence suggesting reduced, not increased, respiratory complications.
Clinical Implications: Supports a risk-based approach rather than blanket discontinuation of GLP-1 RAs before surgery. Multidisciplinary teams should individualize withholding decisions, considering aspiration risk and glycemic control, while acknowledging potential unmeasured confounding.
Key Findings
- Among 296,389 matched pairs, GLP-1 RA users had fewer 30-day postoperative respiratory complications (0.09% vs 0.34%; RR 0.26, 95% CI 0.22–0.29).
- Pulmonary aspiration was less frequent with GLP-1 RAs (0.01% vs 0.03%; RR 0.31, 95% CI 0.20–0.49).
- Both long- and short-acting GLP-1 RAs were associated with reduced respiratory complications.
Methodological Strengths
- Very large nationwide dataset with propensity-score matching to reduce confounding
- Consistent findings across agent classes and multiple respiratory outcomes
Limitations
- Observational design with potential residual confounding and coding misclassification
- Uncertainty about perioperative mitigation measures (e.g., fasting protocols) undertaken
Future Directions: Prospective studies or pragmatic trials should test standardized perioperative protocols for GLP-1 RA management and assess causality and generalizability across surgical contexts.
BACKGROUND: The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has raised concerns about delayed gastric emptying, pulmonary aspiration, and respiratory complications. This study aimed to investigate the association between preoperative GLP-1 RA use and perioperative respiratory complications in type 2 diabetes mellitus. METHODS: We conducted a nationwide propensity-score matched cohort study using the TriNetX database to analyse adults with type 2 diabetes mellitus undergoing surgery in the USA from January 1, 2016, to December 31, 2024. The exposure of interest was use of GLP-1 RA (prescription within 90 days before surgery) compared with individuals not receiving GLP-1 RA. The primary outcome was postoperative respiratory complications within 30 days of surgery, including aspiration. RESULTS: After propensity matching in 296 389 matched pairs (mean [sd] age, 58 [12] yr; 57% female), 259/296 389 (0.09%) receiving GLP-1 RA before surgery had fewer respiratory complications, compared with 1017/296 389 (0.34%) individuals who were not prescribed GLP-1 RA (relative risk, 0.26 [95% confidence interval, 0.22-0.29]; P<0.0001). Pulmonary aspiration occurred in 24/296 389 (0.01%) individuals receiving GLP-1 RA, compared with 78/296 389 (0.03%) not receiving GLP-1 RA (relative risk, 0.31 [95% confidence interval, 0.20-0.49]; P<0.0001). Both long- and short-acting GLP-1 RA use was associated with fewer respiratory complications. CONCLUSIONS: Preoperative GLP-1 RA use was associated with reduced risks of perioperative respiratory complications in people with type 2 diabetes mellitus. These findings were observed in a real-world cohort, with uncertainty about whether measures were undertaken to reduce the risk of aspiration.